In Vitro Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Amphotericin B against <i>Candida auris</i>
The aims of this study were to characterize the antifungal activity of amphotericin B against <i>Candida auris</i> in a static in vitro system and to evaluate different dosing schedules and MIC scenarios by means of semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modelling and s...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e69e23bf110b4853b9214d2e5ab68f2e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | The aims of this study were to characterize the antifungal activity of amphotericin B against <i>Candida auris</i> in a static in vitro system and to evaluate different dosing schedules and MIC scenarios by means of semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation. A two-compartment model consisting of a drug-susceptible and a drug-resistant subpopulation successfully characterized the time-kill data and a modified E<sub>max</sub> sigmoidal model best described the effect of the drug. The model incorporated growth rate constants for both subpopulations, a death rate constant and a transfer constant between both compartments. Additionally, the model included a parameter to account for the delay in growth in the absence or presence of the drug. Amphotericin B displayed a concentration-dependent fungicidal activity. The developed PK/PD model was able to characterize properly the antifungal activity of amphotericin B against <i>C. auris</i>. Finally, simulation analysis revealed that none of the simulated standard dosing scenarios of 0.6, 1 and 1.5 mg/kg/day over a week treatment showed successful activity against <i>C. auris</i> infection. Simulations also pointed out that an MIC of 1 mg/L would be linked to treatment failure for <i>C. auris</i> invasive infections and therefore, the resistance rate to amphotericin B may be higher than previously reported. |
|---|